Skip To Main Content
Xiangying Chu on Muck Rack

Xiangying Chu

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xiangying

Contact Xiangying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer - npj Breast Cancer

|
By Paolo Tarantino, Jaeyoon Cha, Xiangying Chu, Bojana Jovanovic, Andrew Zhou, Melissa Hughes, Douglas Russo, Rinath Jeselsohn, Nancy Lin, Jamie Carter, Tianyu Li, Nabihah Tayob, Elizabeth A. Mittendorf, Stuart J. Schnitt, Shom Goel, Sara M. Tolaney, Busem Binboga Kurt, Molly DiLullo, Eileen Wrabel, Yisang Serenity Chen
| Nature Verified
Abstract HER2-low expression is associated with hormone receptor (HR) expression in HR-positive breast cancer. We aimed to evaluate its association with androgen receptor (AR) among 196 patients with metastatic triple-negative breast cancer (mTNBC). Central determination of AR showed significant enrichment in HER2-low compared with HER2-0 mTNBC (mean: 33.7% vs. 21.4%, p = 0.038), whereas no significant immunological differences were observed.
Open in Who Shared Issue with article?

Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial | Nature Communications

|
By Jingxin Fu, David Yang, Brendan Reardon, Ann H. Partridge, Daniel L. Abravanel, Rinath Jeselsohn, Justin M. Balko, Ian Krop, Xiangying Chu
| Nature Verified
Abstract Patients with hormone receptor-positive (HR + )/HER2- breast cancer may benefit from neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy. The effect of chemotherapy or ICI run-in before combination therapy in this population is unexplored. In this randomized pilot trial, patients with HR + /HER2- breast cancer received two weeks of neoadjuvant nab-paclitaxel or pembrolizumab, with baseline and post-run-in tumor biopsy, followed by combined nab-paclitaxel/pembrolizumab.
Open in Who Shared Issue with article?
See all 2 articles